阿里拉姆制药涨2.28% 股价突破400美元大关

市场透视2025-12-17

北京时间2025年12月17日23时06分，阿里拉姆制药（ALNY.us）股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。机构评级方面，在所有31家参与评级的机构中，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2592285948?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-17 23:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2592285948","market":"us","top_or_hot":-1,"title":"阿里拉姆制药涨2.28% 股价突破400美元大关","media":"市场透视","content":"<div>\n<p>北京时间2025年12月17日23时06分，阿里拉姆制药（ALNY.us）股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。机构评级方面，在所有31家参与评级的机构中，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿里拉姆制药涨2.28% 股价突破400美元大关</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿里拉姆制药涨2.28% 股价突破400美元大关\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 23:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2025年12月17日23时06分，阿里拉姆制药（ALNY.us）股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。机构评级方面，在所有31家参与评级的机构中，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4554","symbol_name":"元宇宙及AR概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b","article_id":"2592285948","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217230647a6ae8c29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592285948","pubTimestamp":1765984007,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2025年12月17日23时06分，阿里拉姆制药股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.36%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰治疗研究的领导者。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4554":"元宇宙及AR概念","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","IE00BF5LJ272.USD":"Legg Mason Martin Currie - Global Emerging Markets A Acc USD","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","BK4585":"ETF&股票定投概念","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0918141887.USD":"安联亚洲实际收益股票基金","LU0348814723.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"A\" (USD) INC  NC","BK4587":"ChatGPT概念","BK4558":"双十一","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0251143458.SGD":"Fidelity Emerging Markets A-SGD","LU1046421795.USD":"富达环球科技A-ACC","BK4588":"碎股","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","LU0651946864.USD":"贝莱德新兴市场股票收益A2","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","BK4565":"NFT概念","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU1051768304.USD":"贝莱德新兴市场股票收益A6","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","ALNY":"阿尔尼拉姆制药公司","LU1515016050.SGD":"Blackrock Emerging Markets Equity Income A6 SGD-H","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4503":"景林资产持仓","LU2148611432.USD":"AZ ALLOCATION BALANCED BRAVE \"AAZ\" (USDHDG) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU1048596156.SGD":"Blackrock Asian Growth Leaders A2 SGD-H","BK4502":"阿里概念","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK4505":"高瓴资本持仓","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK4504":"桥水持仓","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4607":"DeepSeek概念股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4524":"宅经济概念","BK4220":"综合零售","LU1688375341.USD":"贝莱德中国灵活股票基金","LU1823568750.SGD":"Fidelity Global Technology A-ACC SGD","LU0797268264.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (HKD) ACC","BK4527":"明星科技股","BK4526":"热门中概股","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","LU1235294995.USD":"FIDELITY GLOBAL TECHNOLOGY \"A\" (USDHDG) ACC","BK4122":"互联网与直销零售","BK4575":"芯片概念","LU1769817096.USD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERG MARKETS OPPO \"P\" (USD) INC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","LU1769817179.HKD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERG MARKETS OPPO \"P\" (HKD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4579":"人工智能","BK4614":"Manus概念股","LU0047713382.USD":"BGF EMERGING MARKETS \"A2\" ACC","LU1051769294.HKD":"BGF EMERGING MARKETS EQUITY INCOME \"A6\"(HKDHDG) INC","LU2226246903.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT4\" (HKD) ACC","LU1048588211.SGD":"Blackrock Asian Dragon A2 SGD-H","LU0072462343.USD":"贝莱德亚洲巨龙基金","BK4581":"高盛持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK4543":"AI","BK4531":"中概回港概念","BK4534":"瑞士信贷持仓","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0918141705.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AM\" (HKD) INC","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","LU0821914370.USD":"贝莱德亚洲成长领袖A2","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","BK4535":"淡马锡持仓","LU0651947912.USD":"BGF EMERGING MARKETS EQUITY INCOME \"A5G\" (USD) INC","BK4538":"云计算","LU1282648689.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AMG\" (USD) INC","BK4548":"巴美列捷福持仓","LU0328353924.USD":"UBS (LUX) EQUITY SICAV - GLOBAL EMERGING MARKETS OPPORTUNITY (USD) \"P\" (USD) ACC"},"translate_title":"Aliram Pharmaceuticals rose 2.28%, stock price broke through the $400 mark","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALBmain":0.6,"ALNY":1.98},"content_text":"北京时间2025年12月17日23时06分，阿里拉姆制药（ALNY.us）股票出现波动，股价大幅上涨2.28%。截至发稿，该股报400.09美元/股，成交量10.1661万股，换手率0.08%，振幅1.83%。最近的财报数据显示，该股实现营业收入12.49亿美元，净利润2.51亿美元，每股收益1.91美元，毛利10.49亿美元，市盈率1332.23倍。机构评级方面，在所有31家参与评级的机构中，68%的券商给予买入建议，29%的券商给予持有建议，3%的券商给予卖出建议。阿里拉姆制药股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Protagenic Therapeutics Inc C/Wts 26/04/2026 (To Pur Com)、Vyne Therapeutics Inc.、Biovie Inc C/Wts 08/08/2030(To Pur Com)涨幅较大，Aditxt, Inc.、Pmgc Holdings Inc.、Vyne Therapeutics Inc.较为活跃，换手率分别为1632.06%、1060.09%、401.12%，振幅较大的相关个股有Vyne Therapeutics Inc.、Aditxt, Inc.、健永生技，振幅分别为36.18%、34.51%、32.90%。阿里拉姆制药公司简介：艾拉伦制药是RNA干扰(RNAi)治疗研究的领导者。RNA干扰(RNAi)是细胞内一种自然发生的生物通路，用于序列特异性沉默和调控基因表达。艾拉伦有5种药物上市：治疗遗传性转甲状腺素蛋白(hATTR)淀粉样变的Onpattro和Amvuttra，治疗肝性卟啉症的Givlaari，治疗原发性高草酸尿1型的Oxlumo，治疗高胆固醇血症的Leqvio。它也有几个不同治疗领域的临床项目：基因药物；心脏代谢疾病；肝脏感染性疾病以及中枢神经系统/眼部疾病。来自研究合作伙伴的预付费用提高了艾拉伦的现金水平，该公司有望从合作伙伴关系下的药物商业化中看到更多的里程碑和版税。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592285948","isCrawlerRequest":true}